Letter to Editor
BibTex RIS Cite
Year 2021, Volume: 4 Issue: 4, 524 - 525, 15.07.2021
https://doi.org/10.32322/jhsm.922965

Abstract

References

  • Swaroop A, Jaipuriar AS, Gupta SK, et al. Efficacy of a novel fenugreek seed extract (Trigonella foenum-graecum, Furocyst TM) in polycystic ovary syndrome (PCOS). Int J Med Sci 2015; 12: 825.
  • Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed) 2014; 6: 104.
  • Pilar B, Güllich A, Oliveira P, Ströher D, Piccoli J, Manfredini V. Protective role of flaxseed oil and flaxseed lignan secoisolariciresinol diglucoside against oxidative stress in rats with metabolic syndrome. J Food Sci 2017; 82: 3029-36.
  • Yadav K, Ghadge P, Langeh A, Kalbhare S, Phadtare P, Bhoite R. A review on herbal medicinal plant for treatment of polycystic ovarian syndrome (PCOS). AJPRD 2020; 8: 83-7.
  • Haidari F, Banaei-Jahromi N, Zakerkish M, Ahmadi K. The effects of flaxseed supplementation on metabolic status in women with polycystic ovary syndrome: a randomized open-labeled controlled clinical trial. Nutr J 2020; 19: 8.
  • Paschos GK, Yiannakouris N, Rallidis LS, et al. Apolipoprotein E genotype in dyslipidemic patients and response of blood lipids and inflammatory markers to alpha-linolenic acid. Angiology 2005; 56: 49-60.
  • Mirmasoumi G, Fazilati M, Foroozanfard F, et al. The effects of flaxseed oil omega-3 fatty acids supplementation on metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Exp Clin Endocrinol Diabetes 2018; 126: 222-8.
  • Yari Z, Cheraghpour M, Hekmatdoost A. Flaxseed and/or hesperidin supplementation in metabolic syndrome: an open-labeled randomized controlled trial. Eur J Nutr. 2021; 60: 287-98.
  • Heidari Z, Ghasemi-Tehrani H, Fallahzadeh H, Nadjarzadeh A. The effects of flaxseed on weight loss in women with polycystic ovarian syndrome: a randomized controlled trial. Iran J Diabetes Obes 2020; 11: 79-86.

Flaxseed: a promising alternative for polycystic ovarian syndrome therapy

Year 2021, Volume: 4 Issue: 4, 524 - 525, 15.07.2021
https://doi.org/10.32322/jhsm.922965

Abstract

Polycystic Ovarian Syndrome (PCOS) is an endocrine disorder commonly found in females in their reproductive ages and is associated with hirsutism, obesity, menstrual irregularities, and insulin resistance. PCOS management includes the medicinal approach and with the increased incidence of PCOS, herbal approach has been increasing which includes flaxseeds and flaxseed oil but to further explore the benefits, more researches are to be conducted after which they can be included in the medical regime.

References

  • Swaroop A, Jaipuriar AS, Gupta SK, et al. Efficacy of a novel fenugreek seed extract (Trigonella foenum-graecum, Furocyst TM) in polycystic ovary syndrome (PCOS). Int J Med Sci 2015; 12: 825.
  • Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed) 2014; 6: 104.
  • Pilar B, Güllich A, Oliveira P, Ströher D, Piccoli J, Manfredini V. Protective role of flaxseed oil and flaxseed lignan secoisolariciresinol diglucoside against oxidative stress in rats with metabolic syndrome. J Food Sci 2017; 82: 3029-36.
  • Yadav K, Ghadge P, Langeh A, Kalbhare S, Phadtare P, Bhoite R. A review on herbal medicinal plant for treatment of polycystic ovarian syndrome (PCOS). AJPRD 2020; 8: 83-7.
  • Haidari F, Banaei-Jahromi N, Zakerkish M, Ahmadi K. The effects of flaxseed supplementation on metabolic status in women with polycystic ovary syndrome: a randomized open-labeled controlled clinical trial. Nutr J 2020; 19: 8.
  • Paschos GK, Yiannakouris N, Rallidis LS, et al. Apolipoprotein E genotype in dyslipidemic patients and response of blood lipids and inflammatory markers to alpha-linolenic acid. Angiology 2005; 56: 49-60.
  • Mirmasoumi G, Fazilati M, Foroozanfard F, et al. The effects of flaxseed oil omega-3 fatty acids supplementation on metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Exp Clin Endocrinol Diabetes 2018; 126: 222-8.
  • Yari Z, Cheraghpour M, Hekmatdoost A. Flaxseed and/or hesperidin supplementation in metabolic syndrome: an open-labeled randomized controlled trial. Eur J Nutr. 2021; 60: 287-98.
  • Heidari Z, Ghasemi-Tehrani H, Fallahzadeh H, Nadjarzadeh A. The effects of flaxseed on weight loss in women with polycystic ovarian syndrome: a randomized controlled trial. Iran J Diabetes Obes 2020; 11: 79-86.
There are 9 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Letter to the Editor
Authors

Anooja Rani 0000-0002-3974-8716

Publication Date July 15, 2021
Published in Issue Year 2021 Volume: 4 Issue: 4

Cite

AMA Rani A. Flaxseed: a promising alternative for polycystic ovarian syndrome therapy. J Health Sci Med / JHSM. July 2021;4(4):524-525. doi:10.32322/jhsm.922965

Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].

The Directories (indexes) and Platforms we are included in are at the bottom of the page.

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show







The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.

       images?q=tbn:ANd9GcRB9r6zRLDl0Pz7om2DQkiTQXqDtuq64Eb1Qg&usqp=CAU

500px-WorldCat_logo.svg.png

atifdizini.png

logo_world_of_journals_no_margin.png

images?q=tbn%3AANd9GcTNpvUjQ4Ffc6uQBqMQrqYMR53c7bRqD9rohCINkko0Y1a_hPSn&usqp=CAU

doaj.png  

images?q=tbn:ANd9GcSpOQFsFv3RdX0lIQJC3SwkFIA-CceHin_ujli_JrqBy3A32A_Tx_oMoIZn96EcrpLwTQg&usqp=CAU

ici2.png

asos-index.png

drji.png





The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.

COPE-logo-300x199.jpgimages?q=tbn:ANd9GcQR6_qdgvxMP9owgnYzJ1M6CS_XzR_d7orTjA&usqp=CAU

icmje_1_orig.png

cc.logo.large.png

ncbi.pngimages?q=tbn:ANd9GcRBcJw8ia8S9TI4Fun5vj3HPzEcEKIvF_jtnw&usqp=CAU

ORCID_logo.png

1*mvsP194Golg0Dmo2rjJ-oQ.jpeg


Our Journal using the DergiPark system indexed are;

Ulakbim TR Dizin,  Index Copernicus, ICI World of JournalsDirectory of Research Journals Indexing (DRJI), General Impact FactorASOS Index, OpenAIRE, MIAR,  EuroPub, WorldCat (OCLC)DOAJ,  Türkiye Citation Index, Türk Medline Index, InfoBase Index


Our Journal using the DergiPark system platforms are;

Google, Google Scholar, CrossRef (DOI), ResearchBib, ICJME, COPE, NCBI, ORCID, Creative Commons, Open Access, and etc.


Journal articles are evaluated as "Double-Blind Peer Review". 

Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user.  https//dergipark.org.tr/tr/pub/jhsm/page/9535

Journal charge policy   https://dergipark.org.tr/tr/pub/jhsm/page/10912


Editor List for 2022

Assoc. Prof. Alpaslan TANOĞLU (MD)  

Prof. Aydın ÇİFCİ (MD)

Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)

Prof. Murat KEKİLLİ (MD)

Prof. Yavuz BEYAZIT (MD) 

Prof. Ekrem ÜNAL (MD)

Prof. Ahmet EKEN (MD)

Assoc. Prof. Ercan YUVANÇ (MD)

Assoc. Prof. Bekir UÇAN (MD) 

Assoc. Prof. Mehmet Sinan DAL (MD)


Our journal has been indexed in DOAJ as of May 18, 2020.

Our journal has been indexed in TR-Dizin as of March 12, 2021.


17873

Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.